Survey of US correctional institutions for routine HCV testing

American Journal of Public Health

Volumn 105, Issue 1, 2015, Pages 68-71

  Beckwith, Curt G ^a   Kurth, Ann E ^b   Bazerman, Lauri ^a   Solomon, Liza ^c   Patry, Emily ^a   Rich, Josiah D ^a   Kuo, Irene ^d  

^a BROWN UNIVERSITY   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c ABT ASSOCIATES   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84921832072     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2014.302071     Document Type: Article

References (26)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090-1101.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States. Gastroenterology. 2010;138:513-521.
4. Ly KN, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156(4):271-278.
5. Larney S, Kopinski H, Beckwith CG, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. Hepatology. 2013;58:1215-1224.
6. Macalino GE, Vlahov D, Sanford-Colby S, Patel S, Sabin K, Salas C, Rich JD. Prevalence and incidence of HIV, hepatitis B virus, and hepatitis C virus infections among males in Rhode Island prisons. Am J Public Health. 2004;94(7):1218-1223.
7. Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health. 2004;81(1):25-37.
8. Institute of Medicine. Hepatitis and liver cancer. A national strategy for prevention and control of hepatitis B and C. Available at: http://www.iom.edu/reports/2010/hepatitis-and-liver-cancer-a-national-strategy-forprevention-and-control-of-hepatitis-b-and-c.aspx. Accessed October 22, 2013.
9. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(No. RR-19):1-39.
10. Weinbaum C, Lyerla R, Margolis; Centers for Disease Control and Prevention. Prevention and Control of Infections with Hepatitis Viruses in Correctional Settings. MMWR Recomm Rep. 2003;52(No. RR-1):1-36.
11. Roblin DW, Smith BD, Weinbaum CM, Sabin M. Hepatitis C virus screening practices and prevalence in a managed care organization. Am J Manag Care. 2011;17:548-555.
12. Southern WN, Drainoni ML, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat. 2011;18:474-481.
13. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55:1047-1055.
14. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50:1750-1755.
15. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
16. Spaulding AC, Thomas DL. Screening for HCV infection in jails. JAMA. 2012;307(12):1259-1260.
17. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health. 2009;19:245-253.
18. Macalino GE, Dhawan D, Rich JD. A missed opportunity: Hepatitis C screening of prisoners. Am J Public Health. 2005;95(10):1739-1740.
19. Mahowald M, Larney S, Scharff N, et al. The Burden of Hepatitis C Infection in Pennsylvania State Prisons and Implications for Treatment. Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014; Boston, MA. Abstract 630.
20. Spaulding AC, Perez SD, Seals RM, Hallman MA, Kavasery R, Weiss PS. Diversity of release patterns for jail detainees: implications for public health interventions. Am J Public Health. 2011;101(suppl 1):S347-S352.
21. Aghemo A, De Francesco R. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology. 2013;58(1):428-438.
22. Vachon ML, Dieterich DT. The era of direct-acting antivirals has begun: the beginning of the end for HCV? Semin Liver Dis. 2011;31(04):399-409.
23. Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008;47(7):952-961.
24. Farley J, Vasdev S, Fischer B, Haydon E, Rehm J, Farley TA. Feasibility and outcome of HCV treatment in a Canadian federal prison population. Am J Public Health. 2005;95(10):1737-1739.
25. Martin CK, Hostetter JE, Hagan JJ. New opportunities for the management and therapy of hepatitis C in correctional settings. Am J Public Health. 2010;100(1):13-17.
26. Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138(3):187-190.